Drug Safety Matters podcast

#Science #Fitness #Biology #Medicine #Natural Sciences #Uppsala Monitoring Centre #Drug Safety #Healthcare #Medicines Safety #Patient Safety #Pharmacovigilance #Effect

1:00:36

Do you have fond childhood memories of summer camp? For a chance at $250,000, campers must compete in a series of summer camp-themed challenges to prove that they are unbeatable, unhateable, and unbreakable. Host Chris Burns is joined by the multi-talented comedian Dana Moon to recap the first five episodes of season one of Battle Camp . Plus, Quori-Tyler (aka QT) joins the podcast to dish on the camp gossip, team dynamics, and the Watson to her Sherlock Holmes. Leave us a voice message at www.speakpipe.com/WeHaveTheReceipts Text us at (929) 487-3621 DM Chris @FatCarrieBradshaw on Instagram Follow We Have The Receipts wherever you listen, so you never miss an episode. Listen to more from Netflix Podcasts.…

Drug Safety Matters

Series home•Feed

Drug Safety Matters brings you the best stories from the world of pharmacovigilance. Through in-depth interviews with our guests, we cover new research and trends, and explore the most pressing issues in medicines safety today. Produced by Uppsala Monitoring Centre, the WHO Collaborating Centre for International Drug Monitoring.

53 episodes

Drug Safety Matters

updated 6 weeks ago

Series home•Feed

53 episodes

#Science #Fitness #Biology #Medicine #Natural Sciences #Uppsala Monitoring Centre #Drug Safety #Healthcare #Medicines Safety #Patient Safety #Pharmacovigilance #Effect

All episodes

Drug Safety Matters

1
#36 Pregnancy-related pharmacovigilance – Levente Pápai, Lovisa Sandberg & Sara Vidlin 36:44

6 weeks ago36:44

36:44

There are many reasons why use of medical products during pregnancy requires special attention. First and foremost, we want to be sure that the medicine is as safe as possible for both the pregnant person and the unborn child. Unfortunately, the safety profiles of medicines used in pregnancy are often incomplete, which makes it difficult for patients and healthcare professionals to make informed decisions. The Research section at Uppsala Monitoring Centre has a team that is currently focussing their efforts on pregnancy-related pharmacovigilance (PV). In this episode, Data scientists Sara Vidlin and Levente Papai, and Senior Pharmacovigilance scientist Lovisa Sandberg from this team, discuss complexities and challenges of pregnancy-related PV, and new solutions for addressing those challenges. Tune in to find out Why is the world still behind when it comes to pregnancy-related pharmacovigilance? What are the challenges faced by pharmacovigilance assessors wanting to look at pregnancy cases? How can healthcare professionals, patients and carers help assessors overcome these challenges, when reporting pregnancy-related adverse drug events? How can the VigiBase pregnancy algorithm, and other algorithms, support the identification of pregnancy cases? How to use the VigiBase pregnancy algorithm Users of VigiLyze and VigiBase Custom Searches can use the VigiBase pregnancy algorithm as a filter when performing searches. In the qualitative view in VigiLyze, click on “Filter” -> “Patient” -> “Pregnancy” to apply the filter. Want to know more? Read about the VigiBase pregnancy algorithm in this Uppsala Reports article and in this poster , presented at the International Society of Pharmacoepidemiology (ISPE) 2024 annual meeting. EURAP – an international prospective observational study of pregnancies with antiepileptic drugs. EURAP - International Registry of Antiepileptic Drugs and Pregnancy The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - E2B(R3) Individual Case Safety Report (ICSR) Specification and Related Files: ich.org/page/e2br3-individual-case-safety-report-icsr-specification-and-related-files The concePTION project: https://www.imi-conception.eu/ Medical Dictionary for Regulatory Activities (MedDRA®) support documentation: https://www.meddra.org/how-to-use/support-documentation/english Zaccaria C, Piccolo L, Gordillo-Marañón M, et al. Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance. Drug Saf. https://doi.org/10.1007/s4026 Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#35 Veterinary pharmacovigilance part 2 – James Mount 41:42

15 weeks ago41:42

41:42

Human and veterinary pharmacovigilance (PV) share many goals, challenges and approaches. But there are also significant differences, such as the numerous animal species that veterinary PV needs to take into account. In this two-part episode of Drug Safety Matters, James Mount, Veterinary Pharmacovigilance assessor at the Swedish Medical Products Agency, and EU elected chair of the Pharmacovigilance Working Party for veterinary medicinal products, joins the show to talk about veterinary PV practice and its differences and similarities to human PV. In part 2, you will hear about differences in types of ADRs reported for animals as compared to humans, when humans are accidentally exposed to medicines for animals, and vice versa, how the many species and breeds included in veterinary PV affects the coding of ADR reports, breed-specific ADRs – what is safe for one breed of e.g. dog or pig, may not be appropriate for another, the EU Veterinary Big Data Strategy, ... and much more! Links for further reading The public portal of the European Union Veterinary Pharmacovigilance Database . One Health – an integrated approach to the well-being of people, animals and the environment. A survey of veterinary professionals in Sweden , about practices and attitudes in relation to ADR reporting. A review of adverse events in animals and children after secondary exposure to transdermal hormone-containing medicines. The EMA Big Data strategy for veterinary medicines . Data quality framework for medicines regulation | European Medicines Agency (EMA) Small Animal Veterinary Surveillance Network (SAVSNET) - University of Liverpool VetCompass - Royal Veterinary College, RVC Reflection paper on the use of artificial intelligence in the lifecycle of medicines | European Medicines Agency (EMA) Veterinary good pharmacovigilance practices (VGVP) | European Medicines Agency (EMA) Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) | European Medicines Agency (EMA) Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#34 Veterinary pharmacovigilance, Part I – James Mount 47:21

21 weeks ago47:21

47:21

Human and veterinary pharmacovigilance (PV) share many goals, challenges and approaches. But there are also significant differences, such as the numerous species and breeds that veterinary PV needs to take into account. In this two-part episode of Drug Safety Matters, James Mount, Veterinary Pharmacovigilance assessor at the Swedish Medical Products Agency, and EU elected chair of the Pharmacovigilance Working Party for veterinary medicinal products, joins the show to talk about veterinary PV practice and its differences and similarities to human PV. Tune in to find out: What are the similarities and differences between veterinary and human pharmacovigilance? How is animal health connected to public health? What types of adverse events are reported on the veterinary side compared with the human side? What can be found in the EU veterinary pharmacovigilance database? Want to know more? The new veterinary medicines regulation (Regulation (EU) 2019/6) can be found here . The public portal of the European Union Veterinary Pharmacovigilance Database . WHO's information page on One Health , an integrated approach to the well-being of people, animals and the environment. A survey of veterinary professionals in Sweden , about current practices and attitudes in relation to adverse events reporting and the accessibility of product safety information. A review of adverse events in animals and children after secondary exposure to transdermal hormone-containing medicinal products. A study looking at suspected adverse drug reaction reporting in veterinary free‐text clinical narratives . The EMA Big Data strategy for veterinary medicines in the EU. Data quality framework for medicines regulation | European Medicines Agency (EMA) Small Animal Veterinary Surveillance Network (SAVSNET) - University of Liverpool VetCompass - Royal Veterinary College, RVC Reflection paper on the use of artificial intelligence in the lifecycle of medicines | European Medicines Agency (EMA) The Swedish Medical Products Agency's online reporting form for suspected adverse drug reactions in animals (In Swedish). Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#33 Narrative fields and signal assessors, an exploratory study – Joana Félix and Alem Zekarias 38:43

23 weeks ago38:43

38:43

While structured data elements such as patient identifier, medicine name and reaction, are fundamental for adverse event reporting, they may not capture all relevant details. This is where the narrative fields come in, allowing reporters to disclose important contextual information, such as the patient’s full clinical course. But how do PV assessors interact with these narratives in spontaneous reports? What needs and challenges do they experience? These and other questions were addressed in an exploratory interview study by UMC researchers Joana Félix and Alem Zekarias. Tune in to find out: What challenges are PV assessors faced with, when working with narratives? How could automation of certain tasks help streamline narrative analyses in the future? How can reporters craft narratives that effectively document adverse events? Want to know more? Pharmacovigilance assessors’ experiences interacting with narrative fields in spontaneous reports: an exploratory interview study – poster presented at the 23rd ISoP Annual Meeting “Global Perspectives on Pharmacovigilance in the Digital Age and Advanced Therapeutics” , 1–5 October 2024 Montreal, Canada. Current Challenges in Pharmacovigilance: Pragmatic Approaches , by The Council for International Organisations of Medical Sciences (CIOMS). See page 133 on the role of narratives in good case management practices. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#32 Pharmacovigilance in older adults – Giovanni Furlan 47:51

28 weeks ago47:51

47:51

Medication-related-harm (MRH) is especially prevalent in older adults due to changing physiology as the body ages, increased frailty, and the incidence of polypharmacy in this patient group. Giovanni Furlan, Worldwide Safety Site Lead for Thessaloniki of Pfizer discusses what makes this patient group so vulnerable to adverse drug reactions, how poor representation and using age alone to define older adults exacerbates this problem, and suggests ways forward in monitoring drug safety in older patients. Tune in to find out: What makes older adults especially at risk of experiencing adverse drug reactions and medication errors Why frailty is far more useful than age in predicting adverse drug reaction risk How pharmacovigilance in older patients may be improved through pharmaceutical practice and better representation in clinical trials. Want to know more? This interview all started with Giovanni's Uppsala Reports article on how age is insufficient a measure of adverse event risk. Read it here . For a summary of the key points discussed in this interview, read Giovanni’s paper on the status of drug safety in geriatric patients . If our discussion of frailty piqued your interest, read this paper on the biology of frailty and how this impacts clinical pharmacology, this multi-centre cohort study that shows frailty is significantly correlated with MRH, and this commentary advocating for consideration of MRH as a geriatric syndrome, which needs to be managed as such. As Giovanni mentioned in the interview, Harlan Krumholz was the first to describe post-hospital syndrome. Learn more about this syndrome by reading his paper . For more on prescribing cascades, their prevention, detection, and reversal, read this paper by Brath and colleagues. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#31 A guide to reporting disproportionality analyses – Michele Fusaroli and Daniele Sartori 42:45

32 weeks ago42:45

42:45

Disproportionality analyses are a mainstay of pharmacovigilance research, but without clear guidelines, they often lead to confusion and misinterpretation. Enter the READUS-PV statement: the first-ever guide for reporting disproportionality analyses that are replicable, reliable, and reproducible. Tune in to find out: The history of reporting guidelines in pharmacovigilance and why the READUS-PV guidelines were created Why there has been a spike in the publication of disproportionality analyses in recent years and what this means for their reliability What it means to publish “good” pharmacovigilance science Want to know more? Read the READUS-PV guidelines , why they were created , and why they are important . In 2021, Khouri and colleagues showed that current methods and models used for disproportionality analyses are unreliable , and Mouffak and colleagues found that there is a tendency to overstate results in published disproportionality analyses . A book on data mining techniques in Pharmacovigilance by Poluzzi and colleagues delves deeper into this exponential increase in disproportionality analyses . This paper elaborates on the Delphi technique, and how it is used to gather data from reviewers to achieve scientific consensus on a problem. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
Uppsala Reports Long Reads – Weeding out duplicates to better detect side effects 25:02

37 weeks ago25:02

25:02

Duplicate reports are a big problem when it comes to signal detection, but with the help of machine learning and new ways of comparing reports, we may more effectively detect them. This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance news site, brought to you in audio format. Find the original article here . After the read, we speak to author Jim Barrett, Senior Data Scientist at UMC, to learn more about the duplicate detection algorithm and UMC’s work to develop AI resources for pharmacovigilance. Tune in to find out: How the new algorithm handles duplicates in VigiBase About different approaches for developing algorithms Why it can be challenging to evaluate the performance of an algorithm Want to know more? Listen to the Drug Safety Matters interview with Michael Glaser about his Uppsala Reports article “Ensuring trust in AI/ML when used in pharmacovigilance” and check out the episode’s extensive list of links for more on AI in pharmacovigilance. Artificial intelligence in pharmacovigilance – value proposition and the need for critical appraisal , a presentation by Niklas Norén, Head of Research at UMC, given at University of Verona in April 2024. Finally, don’t forget to subscribe to the monthly Uppsala Reports newsletter for free regular updates from the world of pharmacovigilance. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
Uppsala Reports Long Reads – Ensuring trust in AI/ML when used in pharmacovigilance 30:18

45 weeks ago30:18

30:18

Ensuring trust in AI is vital to fully reap the benefits of the technology in pharmacovigilance. Yet, how do we do so while grappling with its ever-growing complexity? This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance news site, brought to you in audio format. Find the original article here . After the read, we speak to one of the authors of the article, Michael Glaser, to learn more about how AI and ML has been used in pharmacovigilance so far, and what needs to happen to ensure its continued use in the field. Tune in to find out: ● How AI and ML are being used today in pharmacovigilance processes ● Why a mindset change is necessary to make full use of AI/ML in pharmacovigilance ● How we may best move forward to implement AI/ML into healthcare. Want to know more? To know more about how AI and ML are being used in pharmacovigilance currently, read this scoping review . To know more about future trends of the use of AI in Biopharma, read this Accenture survey . Despite there being major interest in ML and AI to do more than task automation, there are a number of barriers to its implementation in healthcare. Check out this future-focused paper on the use of AI/ML in pharmacovigilance that details how to utilise it to its fullest potential. A mindset shift is necessary in terms of how we think about data, in terms of sharing, how to generate data required to effectively train AI/ML models. A validation framework must be developed for AI-based pharmacovigilance systems . One suggestion is to do so using a risk-based approach . While there is much interest in using recently developed AI technologies such as chatGPT, preliminary studies like this one suggest that the technology has a ways to go to be useful in pharmacovigilance. The World Health Organization have published an extensive guideline on the ethics and governance of AI for health. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#30 Preventing and reporting medication errors – Rabat CC & UMC 33:58

52 weeks ago33:58

33:58

Look-alike medicines, unclear communication and distractions during administration – medication errors may occur for many different reasons. They all have in common that they are unintended mistakes in the drug treatment process that may or may not lead to patient harm. In this episode Ghita Benabdallah and Loubna Alj from the national pharmacovigilance centre of Morocco, and Alem Zekarias from Uppsala Monitoring Centre discuss how we can prevent medication errors from occurring – and, when they do occur, make sure that they are reported as such. Tune in to find out: What are the most common causes for medication errors? How should strategies for preventing medication errors be devised? How does the assessment of suspected medication error reports differ from “regular” ADR signal assessment? What can be done to encourage healthcare professionals to report medication errors? Want to know more? In March 2024, WHO published this systematic review of the global burden of preventable medication-related harm in healthcare. According to this 2021 article in BMJ , an estimated 237 million medication errors occur in England every year. Avoidable adverse drug events were calculated to cost the National Health Service an annual sum of GBP 98 462 582 per year, consuming 181 626 bed-days, and causing/contributing to 1708 deaths. This 2012 meta-analysis confirmed what had been suggested in several observational studies: that preventable adverse drug reactions are a significant healthcare burden. The European Medicines Agency (EMA) has a dedicated webpage with recommendations, guidelines, legal requirements and a good practice guide on medication errors. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#29 When medicines change our behaviour – Michele Fusaroli 30:30

1 year ago30:30

30:30

Medicines can affect our personality in positive ways, but they may also lead to destructive behaviours that can damage our relationships, finances, and overall quality of life. Michele Fusaroli from the University of Bologna explains how to diagnose and treat drug-induced impulse control disorders. Tune in to find out: Which medicines may cause impulsivity What the ‘four knights’ of impulsivity are How patient stories can help detect these conditions Want to know more? This review by Daniel Weintraub summarises twenty years of research on impulse control disorders in Parkinson’s disease. In 2003, Driver-Dunckley and colleagues in the US published the first case series linking pathological gambling to dopamine agonists . In 2016, the US Food and Drug Administration warned about impulse-control problems associated with the antipsychotic drug aripiprazole . Michele and colleagues in Italy have investigated the mechanisms and burden of drug-induced impulsivity. In their 2024 guidelines for managing impulsivity in Parkinson's disease, an expert consensus group highlighted the pivotal role of caregivers and of psychosocial interventions. Finally, these are the Drug Safety Matters episodes cited in the interview: Catching black swans When drugs damage the liver Empowering patients as partners Why we should listen to patients Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#28 Catching black swans – François Montastruc 27:21

1 year ago27:21

27:21

Serious and unexpected adverse drug reactions – the ‘black swans’ of pharmacovigilance – can place enormous strain on safety monitoring systems. Drawing examples from the COVID-19 pandemic, François Montastruc from Toulouse University Hospital explains how we can get better at dealing with the unpredictable. Tune in to find out: What Nassim Nicholas Taleb’s ‘black swan’ theory has to do with pharmacovigilance What makes an adverse drug reaction a black, white, or grey swan Why flexibility and communication are key to patient safety Want to know more? Here are the research articles cited in the episode: Quality of reporting of adverse events in clinical trials of COVID-19 drugs: systematic review Psychiatric disorders and hydroxychloroquine for COVID-19: a VigiBase study Hepatic disorders with the use of remdesivir for COVID-19 Serious bradycardia and remdesivir for COVID-19: a new safety concern Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: a missed opportunity for a rapid return of experience Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: data from the French network of regional pharmacovigilance centres Teaching pharmacovigilance to French medical students during the COVID-19 pandemic: interest of distance learning clinical reasoning sessions If you enjoyed this podcast, check out these related episodes from the Drug Safety Matters archive: Reforming pharmacovigilance education Lessons in pandemic pharmacovigilance Intuition in pharmacovigilance Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#27 When drugs damage the liver – Rita Baião 28:30

1 year ago28:30

28:30

The liver is the primary site for drug metabolism in the body, but it can be severely damaged by medicines or their toxic compounds. Rita Baião from the North Lisbon University Hospital Center reviews what pharmacovigilance professionals should know about drug-induced liver injury (DILI). Tune in to find out: Who is most at risk of developing DILI How to diagnose the condition and control the damage How to assess case reports of DILI Want to know more? This infographic in Nature Reviews nicely summarises the mechanisms, diagnosis, and management of drug-induced liver injury. In this report , the Council for International Organizations of Medical Sciences provides a global perspective on DILI detection, susceptibility factors, outcomes, and more. In this Drug Safety article , industry representatives outline how to identify, mitigate, and communicate the risk of DILI during drug development. The PRO-EURO DILI NETWORK coordinates research efforts on DILI across Europe and provides a forum to exchange knowledge and training on the topic. Similar initiatives include the Spanish DILI Registry and the Latin American DILI Network . The free online tool LiverTox contains up-to-date information on drug-induced liver injury for medicines and herbal products. To learn more about post-marketing surveillance and clinical care of DILI, check out Uppsala Monitoring Centre’s free online course on the topic. For more on the clustering algorithm vigiGroup, revisit this interview with UMC scientists Jim Barrett and Joe Mitchell. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#26 What's trending in pharmacovigilance? – Angela Caro 28:06

1 year ago28:06

28:06

What did the drug safety community achieve in 2023 and how will the field develop in 2024? As the year comes to a close, we asked Angela Caro, president of the International Society of Pharmacovigilance (ISoP), to walk us through current and future trends in pharmacovigilance. Tune in to find out: Why patient engagement is a growing priority What challenges exist in the Latin American region Which topics will be in the spotlight next year Want to know more? ISoP is a non-profit society open to anyone with an interest in pharmacovigilance. Through 14 chapters and 13 special interest groups , the society works to enhance the safe and proper use of medicines across countries. Their latest annual meeting took place in Bali, Indonesia in November 2023, while the next one will take place in Montreal, Canada in October 2024. To learn more about ISoP’s activities in patient engagement and pharmacogenomics, listen to these episodes from the Drug Safety Matters archive: Empowering patients as partners Tailoring drug therapy to your genes Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#25 A week in the name of medicines safety – part 2 33:13

1 year ago33:13

33:13

To mark #MedSafetyWeek , which took place from 6–12 November, we’re releasing a special two-part episode on pharmacovigilance communication campaigns. In this second part, we hear from three #MedSafetyWeek veterans – Anne-Cécile Vuillemin from the Ministry of Health in Luxembourg, Ban Al-Shimran from the Iraqi Ministry of Health, and Frieda Shigwedha from the Therapeutic Information and Pharmacovigilance Centre in Namibia – about what makes a successful campaign. Tune in to find out: Why you should always tailor your communication strategy to your setting How to deal with the financial, cultural, and logistical challenges of campaign planning What to keep in mind if you are new to #MedSafetyWeek Want to know more? You can read a summary of this episode on the Uppsala Reports news site. To learn more about #MedSafetyWeek, check out the hashtag online and visit the campaign website , where you will also find free social media materials in several languages. This is the second of a two-part episode on pharmacovigilance communication campaigns. Listen to the first part here . Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#24 A week in the name of medicines safety – part 1 27:09

2 years ago27:09

27:09

To mark #MedSafetyWeek , which takes place from 6–12 November, we’re releasing a special two-part episode on pharmacovigilance communication campaigns. In this first part, we speak to Mitul Jadeja from the Medicines and Healthcare products Regulatory Agency in the UK about under-reporting and how initiatives like #MedSafetyWeek can help draw attention to medicines safety. Tune in to find out: Why under-reporting plagues all pharmacovigilance systems What regulators can do to encourage people to report side effects Why we need reports from both patients and healthcare professionals Want to know more? Here are the studies cited in the episode: A BMJ study in 2022 measured the burden and associated cost of adverse drug reactions , polypharmacy and multimorbidity at a hospital in the UK. In 1976, Inman proposed a theoretical model, known as the ‘seven deadly sins’, to explain why healthcare professionals fail to report adverse drug reactions. This recent systematic review in Drug Safety expands on that. The SCOPE Joint Action project aimed to enhance pharmacovigilance in the EU and delivered practical guidance for regulators. The first UK study to compare Yellow Card reports from patients and healthcare professionals was published in 2012. To join the #MedSafetyWeek campaign next week, follow the hashtag online and check out the campaign website for free social media materials. Finally, don’t forget to tune in on 13 November for part 2 of this podcast, where we’ll hear from #MedSafetyWeek advocates in Iraq, Luxembourg, and Namibia about their experience with the campaign. Read a preview of the conversation on Uppsala Reports . Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
Uppsala Reports Long Reads – The colour of signals 33:59

2 years ago33:59

33:59

Herbal remedies have been used for thousands of years to treat what ails us. Yet why do we still know so little about their potential side effects compared to modern medicines? This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance news site, brought to you in audio format. Find the original article here . After the read, we speak to author Daniele Sartori to learn more about the challenges in herbal pharmacovigilance. Tune in to find out: Why the risks of herbals are rarely discussed How to encourage safety data collection for herbals How to improve herbal nomenclature and regulation Want to know more? Here are some of the resources cited in the episode: Underreporting of adverse reactions to herbal remedies is driven by our attitude towards herbals themselves , but also by a lack of training on herbal medicines in healthcare curricula. It is possible to safely use herbal medicines together with other medicines, but we must keep in mind some critical issues related to their interaction . Simple videos can dramatically increase public awareness of ADR reporting schemes. Kew Gardens’ Medicinal Plant Names Services offers a systematic overview of medicinal plants and their accepted scientific names. The American Botanical Council suggests methods to uncover attempts to adulterate plant extracts . For a comprehensive overview of herbal pharmacovigilance, check out this recent book by Joanne Barnes and colleagues covering advances, challenges, and international perspectives in the field. For more on Daniele’s scoping review of signals or the thorny nomenclature of medicinal plants, listen to these episodes from the Drug Safety Matters archive: The evidence for signals Navigating the plant names jungle Finally, don’t forget to subscribe to the monthly Uppsala Reports newsletter for free regular updates from the world of pharmacovigilance. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
Uppsala Reports Long Reads – Empowering patients as partners 42:43

2 years ago42:43

42:43

A patient's perspective can ensure safe medical care and lead to new insights that traditional research may overlook. But how do we best harness that perspective to improve patient outcomes? This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance news site, brought to you in audio format. Find the original article here . After the read, we speak to Manal Younus, who authored the article, to learn more about patient engagement and its benefits for medicines safety. Tune in to find out: How regulators and healthcare professionals can effectively engage patients How patients can get involved in drug safety monitoring What the pharmacovigilance community learned from the valproate case Want to know more? In 2022, the Council for International Organizations of Medical Sciences (CIOMS) published a comprehensive report on patient involvement in the development, regulation and safe use of medicines . They also recorded a webinar to summarise the report’s main conclusions. The International Society of Pharmacovigilance (ISoP) runs a patient engagement group to advance patient involvement in the safety monitoring of medicines. The Valproate toolkit , developed by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), supports healthcare professionals in advising women of childbearing age about the risks and benefits of valproate therapy. PatientsLikeMe is a digital platform where patients can share personal health stories, connect to peers, and learn about different conditions and treatments. For more on patient engagement and communication, check out these episodes from the Drug Safety Matters archive: Why we should listen to patients The challenge of rare diseases How to talk about risks Finally, don’t forget to subscribe to the monthly Uppsala Reports newsletter for free regular updates from the world of pharmacovigilance. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#23 Assessing safety in clinical trials – Marianne Lunzer & Sanja Prpić 31:06

2 years ago31:06

31:06

Medicines safety monitoring is a continuous process that begins with pre-marketing clinical trials and continues with post-marketing studies to fill any gaps in knowledge. With Marianne Lunzer from AGES and Sanja Prpić from HALMED, we review the pros and cons of various study types and the importance of testing medicines on diverse populations. Tune in to find out: How pre- and post-approval safety studies are connected Why safety assessors can request studies in underrepresented populations How new regulations are impacting safety assessments in the EU Want to know more? This review in Trials summarises the methodological challenges of assessing drug safety in clinical trials, while this study in Clinical and Translational Science reviews how sex, racial, and ethnic diversity in clinical trials have changed in recent years. Post-authorisation safety studies can be imposed or voluntary and can be carried out as clinical trials or as non-interventional studies. Read about the differences on the European Medicines Agency’s website. Large simple trials can control for biases in observational research while still providing results that are generalisable to real-world use. This review in Drug Safety explains why. The new Clinical Trials Regulation harmonises how EU trials are assessed and supervised for increased safety and transparency. As part of these efforts, the SAFE CT project aims to facilitate clinical trial coordination and safety assessments in the EU. For more on clinical trials, revisit this conversation with Peter Doshi on restoring invisible and abandoned trials. This episode is the last of a three-part series on sources of evidence in pharmacovigilance. Listen to the first two episodes here: The evidence for signals Unlocking the power of real-world data Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#22 Reforming pharmacovigilance education – Michael Reumerman 32:54

2 years ago32:54

32:54

Healthcare professionals are key players in medicines safety but they often lack the time or knowledge to report adverse drug reactions. To change that, we need to urgently rethink how we teach pharmacovigilance, argues Michael Reumerman from Amsterdam University Medical Centers. Tune in to find out: How real-life education can benefit healthcare students Which educational intervention can be most impactful How adverse drug event managers can improve pharmacovigilance Want to know more? In his PhD thesis , Michael details the current state of pharmacovigilance education and all the real-life interventions he and his colleagues have tested in the Netherlands so far. As part of an international collaboration , staff at Amsterdam UMC have helped set up the European Open Platform for Prescribing Education (EurOP2E) , an online collection of problem-based, open teaching resources to improve clinical pharmacology and therapeutics education. The World Health Organization’s Guide to Good Prescribing provides a six-step guide for students to the process of rational prescribing – but the time has come to update both its content and form . In 2018, the Netherlands Pharmacovigilance Centre Lareb developed a core curriculum for pharmacovigilance education in universities. Whether you’re a healthcare professional or not, check out Uppsala Monitoring Centre’s growing collection of self-paced e-learning courses to learn about different aspects of pharmacovigilance. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#21 Unlocking the power of real-world data – Patrick Ryan 33:42

2 years ago33:42

33:42

The vast amount of real-world data collected during routine clinical care is a treasure trove of safety information – but there are challenges to overcome before this rich source of evidence can be applied to pharmacovigilance. Patrick Ryan from Johnson & Johnson discusses how to harness real-world data for patient safety. Tune in to find out: How real-world data is collected and analysed Which pharmacovigilance processes will benefit most from it How to make data accessible without infringing patient privacy Want to know more? Review the basics of real-world data and its use in the medicines life cycle in Pharmaceutical Medicine , or read up on the opportunities and challenges for pharmacovigilance in Clinical Pharmacology & Therapeutics . In partnership with the Observational Health Data Sciences and Informatics (OHDSI) and the European Health Data & Evidence Network (EHDEN) consortia, UMC researchers are exploring how real-world data can help prioritise and validate signals in pharmacovigilance. Read about their latest collaboration on Uppsala Reports . Another important player in the real-world data space is the Data Analysis and Real World Interrogation Network (DARWIN) , which aims to provide timely and reliable evidence from real-world healthcare databases in the EU to improve the safety and effectiveness of medicines. For more on real-world evidence and the challenges of working with big data, don’t miss the Voice of EHDEN podcast or this conversation with Elena Rocca from the Drug Safety Matters archive. This episode is the second of a three-part series on sources of evidence in pharmacovigilance. Listen to the other two episodes here: The evidence for signals Assessing safety in clinical trials Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#20 The evidence for signals – Daniele Sartori 45:41

2 years ago45:41

45:41

Spontaneous reports of adverse drug reactions are a common source of evidence in pharmacovigilance, but as the science evolves, so do the types of data used to find and assess signals. Uppsala Monitoring Centre’s Daniele Sartori reviews how signal detection practices have changed over time. Tune in to find out: Which features of case reports are most often used to assess causality Why pharmacovigilance experts should report clinical assessments clearly How to shorten the time between signal detection and communication Want to know more? Check out the full scoping review that inspired this episode. In 2002, Meyboom and colleagues discussed criteria to select and follow up on signals. In the first chapter of Uncertainty in Pharmacology , Aronson explains the difference between evidence for a mechanism and evidence from a mechanism. In 2018, Murad and colleagues published a method to evaluate the quality of evidence in a series of case reports. UMC scientists have shown how chemical information can support timely signal detection. This episode is the first of a three-part series on sources of evidence in pharmacovigilance. Listen to the other two episodes here: Unlocking the power of real-world data Assessing safety in clinical trials Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
Uppsala Reports Long Reads – Unmasking data in the COVID-19 vaccine era 21:19

2 years ago21:19

21:19

Most pharmacovigilance professionals will have heard of masking – a statistical issue where reports for one drug hide signals for other drugs. But the problem gained fresh attention when record amounts of reports began piling up for the COVID-19 vaccines. How should we be unmasking data in the COVID-19 vaccine era? This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance magazine, brought to you in audio format. Find the original article here . After the read, we speak to data scientist Sara Vidlin, who authored the article, to learn more about masking and how to deal with it. Tune in to find out: How masking evolves with the data Which methods can be used to unmask data What other pitfalls to watch out for when performing quantitative analyses Want to know more? In the very beginning of the vaccine rollout, the USA FDA observed how early signals for COVID-19 vaccines were delayed because of other drugs masking them, highlighting how masking is not a static phenomenon. In 2013, Uppsala Monitoring Centre developed a simple strategy to uncover masking by identifying and removing influential outliers. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#19 Lessons in pandemic pharmacovigilance – Elena Rocca 33:11

2 years ago33:11

33:11

The COVID-19 pandemic forced pharmacovigilance experts to revisit their processes to deal with unprecedented volumes of data and catch unexpected safety issues. Elena Rocca from Oslo Metropolitan University reviews the challenges of a global healthcare emergency – and what it can teach us about the science of drug safety. Tune in to find out: How to handle uncertain evidence Why clinical expertise matters in the age of big data Why pharmacovigilance requires interdisciplinary thinking Want to know more? In the article that inspired this episode, Elena Rocca and Birgitta Grundmark describe the practical, conceptual, and ethical challenges pharmacovigilance experts were faced with during the pandemic. See also this review by Annette Rudolph and colleagues at Uppsala Monitoring Centre on the unique challenges of a global vaccination campaign. Elena’s reflections on big data pharmacovigilance and its ethical implications were inspired by Sabina Leonelli’s work on big data biology and mathematician Cathy O’Neil’s Weapons of Math Destruction . The CauseHealth Pharmacovigilance project, a collaboration between UMC and the NMBU Centre for Applied Philosophy of Science in Norway, ran between 2018 and 2021. For more philosophical inspiration, revisit this interview with Eugene van Puijenbroek on intuition in pharmacovigilance or this Uppsala Reports Long Read on new approaches to causality. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#18 The IDMP standards explained – Malin Fladvad & Olle Lagerlund 23:06

3 years ago23:06

23:06

The Identification of Medicinal Products (IDMP) standards promise to harmonise how pharmaceutical products and substances are described around the world. But how will that benefit patients and who will make sure the standards are properly implemented? Uppsala Monitoring Centre’s Malin Fladvad and Olle Lagerlund discuss the advantages and challenges of this global standardisation effort. Tune in to find out: What the IDMP standards cover How Uppsala Monitoring Centre will help create and maintain them What is expected of other key stakeholders Want to know more? UNICOM’s ‘IDMP in a capsule’ explains how the IDMP standards work throughout the life cycle of a medicinal product and is available as a handbook and video tutorial. Healthcare consultant Christian Hay discusses how IDMP will improve medication safety worldwide in Uppsala Reports. Development and implementation of the standards are led by the International Organization for Standardization (ISO), who described the key benefits of the project in this article from 2016. The IDMP standards for dose form and characteristics will be provided by the European Directorate for the Quality of Medicines & HealthCare (EDQM) , and those for units by the Unified Code for Units of Measure (UCUM) . You can learn more about Uppsala Monitoring Centre’s role in the IDMP project and how the standards will affect the WHODrug Global drug dictionary on our website . Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#17 Why we need vaccine surveillance systems – Madhava Balakrishnan 27:30

3 years ago27:30

27:30

Public trust in vaccines hinges on their safety – but to make sure vaccines are safe, we must have systems in place to detect and manage any side effects. Dr Madhava Ram Balakrishnan, medical officer for vaccine safety at the World Health Organization, discusses how to build an effective vaccine surveillance system and how to respond to safety crises when they occur. Tune in to find out: How safety surveillance differs between vaccines and drugs What the most common side effects of vaccines are How to address the public’s concerns on vaccine safety Want to know more? The World Health Organization offers free manuals on surveillance and causality assessment of adverse events following immunisation (AEFI). They also maintain an AEFI causality assessment software where you can practice on real or sample cases, and an online course on the principles and processes of AEFI causality assessment . In the BMJ Global Health, Madhava Balakrishnan and colleagues review how online communication affects immunisation stress-related responses and how to address public anxieties around vaccine safety. For more on vaccines and risk communication, check out these episodes from the Drug Safety Matters archive: How to talk about risks Talking about vaccine safety Convincing the vaccine hesitant Keeping vaccines safe Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#16 How drug safety can help fight resistant bugs – Jean Marie Vianney Habarugira & Albert Figueras 33:42

3 years ago33:42

33:42

Managing antimicrobial resistance (AMR) will require innovative solutions from many different disciplines. Could pharmacovigilance be one of them? Jean Marie Vianney Habarugira and Albert Figueras, who have been investigating how drug safety tools could help track AMR, think it’s time the two communities joined forces for good. Tune in to find out: How to code adverse drug reactions for optimal AMR surveillance How to use pharmacovigilance networks to track resistant pathogens and falsified antimicrobials Why collaborating with AMR specialists will benefit the drug safety community Want to know more? In their study, Jean Marie and Albert shortlisted 17 MedDRA codes used to report AMR-related adverse drug reactions in a global and a national pharmacovigilance database . Pharmacovigilance tools could be especially useful in estimating the burden of AMR in low-resource communities that lack diagnostic lab capacity. Jean Marie’s research was inspired by this article in Uppsala Reports , which defined antimicrobial resistance as an overlooked adverse event. Since 2015, the World Health Organization’s GLASS (Global Antimicrobial Resistance and Use Surveillance System) has been used to collect, analyse, and share AMR data around the world. Interested in AMR from a social perspective? Then don’t miss this Drug Safety Matters episode on behaviour change communication. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#15 Safety of HIV medications – Henry Zakumumpa 33:19

3 years ago33:19

33:19

With the right care, people infected with HIV can lead long and healthy lives. But as with any life-long medical treatment, it is important to acknowledge and manage any side effects. Henry Zakumumpa from Makerere University School of Public Health tells us about the potential harms of new HIV therapies and the challenges faced by pharmacovigilance specialists in Uganda. Tune in to find out: How dolutegravir-based HIV therapies compare to earlier regimens How pharmacovigilance data can help shape HIV treatment guidelines Why we should empower patients to share concerns about their healthcare Want to know more? Hyperglycemia, insomnia and reduced libido were the most common side effects observed by Ugandan clinicians in patients taking dolutegravir. Nurses are the backbone of HIV disease management in Uganda and could play an important role in pharmacovigilance activities as well. Henry Zakumumpa’s research was supported by Uppsala Monitoring Centre in collaboration with CARTA, the Consortium for Advanced Research Training in Africa , which is working to build up research capacity in public health. The World Health Organization’s resources on HIV/AIDS include easily digestible information for patients, epidemiological data on disease spread, and current guidelines for prevention and treatment. For more on African and patient-centred pharmacovigilance, check out these episodes from the Drug Safety Matters archive: Advancing pharmacovigilance in Africa Why we should listen to patients Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#14 Advancing pharmacovigilance in Africa – Eleni Aklillu & Abbie Barry 37:20

3 years ago37:20

37:20

Access to medical products has increased considerably in Africa in recent years, but safety monitoring systems haven’t exactly kept pace and many African countries still struggle to address safety issues. We sat down with Eleni Aklillu and Abbie Barry of the PROFORMA project to learn about their efforts to strengthen pharmacovigilance capacity in East Africa – especially within public health programmes. Tune in to find out: How comorbidities and genetic variation affect drug safety monitoring Why pharmacovigilance centres should strengthen their ties with academia How to apply the PROFORMA model elsewhere Want to know more? Low- and middle-income countries like the PROFORMA target nations face unique challenges in establishing robust pharmacovigilance systems, as described in this comprehensive review . PROFORMA’s baseline assessment of national pharmacovigilance systems in Ethiopia, Kenya, Rwanda, and Tanzania identified gaps and laid the groundwork for targeted interventions. Their subsequent assessment of pharmacovigilance capacity within the neglected tropical diseases programmes highlighted the urgent need for collaboration between those programmes and the national pharmacovigilance centres. You can read about PROFORMA’s accomplishments in more detail on Uppsala Reports and on the PROFORMA website , which also lists the consortium’s publications and upcoming events. For more on the influence of genetic factors on drug response, revisit this interview with UMC’s pharmacogenetics specialist Qun-Ying Yue or this Uppsala Reports Long Read on pharmacogenomics research in Africa. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
#13 How to talk about risks – Alexandra Freeman 38:16

3 years ago38:16

38:16

People’s perception of risk can vary greatly from person to person, making it challenging for healthcare professionals to communicate benefits and harms of medicines in a balanced fashion. Alexandra Freeman from the Winton Centre for Risk and Evidence Communication discusses how to give patients the information they need to decide what's best for them. Tune in to find out: Why people perceive risks so differently Why medical communicators should strive to inform rather than persuade How to communicate in a trustworthy fashion Want to know more? There is no right way to communicate evidence to patients, but there are a few things you can do to avoid getting it wrong. Conventional communication techniques are good for persuading people – but when the aim is to inform, the principles of evidence communication should be applied instead. Graphics can help people translate abstract numbers into contextualised risks they can relate to, like these visuals that illustrate the risk of blood clots with the AstraZeneca COVID-19 vaccine. These evidence-based guidelines can help professional communicators illustrate the personalised risk of dying from COVID-19. The Winton Centre offers plenty of resources on risk and evidence communication, including free e-learning courses for healthcare professionals, the Risky Talk podcast with statistician David Spiegelhalter, and the RealRisk tool to help healthcare professionals and communicators extract the right statistics from academic papers. For more on communicating benefits and harms in pharmacovigilance, revisit this Drug Safety Matters episode on vaccine safety communication. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Drug Safety Matters

1
Uppsala Reports Long Reads – Safety issues faced by refugee communities 25:08

3 years ago25:08